HOME > Clinical Trial

Clinical Trial

Clinical studies in progress

As of March 2012

Study on cervical carcinoma

Study name: JGOG1068
Subject  Patients with stage lb2-IVa cervical cancer after concurrent chemoradiotherapy (CCRT)
Treatment  Phase Ⅰ study of combination chemotherapy with Irinotecane hydrochroride (CPT-11) and Nedaplatin for cervical cancer after CCRT
Accrual Period  January 2012 - December 2013
Target number of patients  from 12 to 48

Study on carcinoma of the corpus uteri

Subject  planned
Treatment   
Accrual Period   
Target number of patients   

Study on Ovarian cancer

Study name: JGOG3018: suspended
Subject  Patients with recurrent/recrudescent, platinum-resistant Mullerian carcinoma (Epithelial ovarian, primary fallopian tube, and peritoneal cancers) 
Treatment  Phase III, randomized, comparative study of liposomal doxorubicin (PLD) at 40 and 50 mg/m2 
Accrual Period  February 2010 – January 2013 
Target number of patients  Number per group: 206  Total number: 412 
Study name: GOTIC-001/JGOG3019
Subject  Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Treatment  Randomized,comparative study of weekly IV paclitaxel + IV carboplatin every 3 weeks and IV paclitaxel + IV carboplatin every 3 weeks.
Accrual Period  May 2010 – April 2013
Target number of patients  Number per group: 120 (Phase II) /746 (Phase III)
Study name: JGOG3020
Subject  Patients with surgical stage I epithelial ovarian cancer
Treatment  Phase III, randomized, comparative study of surgery plus adjuvant chemotherapy and surgery alone.
Accrual Period  April 2012 - March 2017
Target number of patients  Number per group: 310  Total number: 620
  • Organization Chart
  • Board of Directors
  • Crinical Trial
  • Achievement
  • JGOG COI Policy
  • Newsletter
  • Related Links

JGOG Administration Office
4F, Komatsu Building, 6-22, Kagurazaka, Shinjuku-ku,
Tokyo, 162-0825,
Japan
E-mail : info-e@jgog.gr.jp

top